- Published on
Infectious disease and microbiology – Mucormycosis
Mucormycosis is a life-threatening opportunistic fungal infection characterized by vascular invasion, thrombosis, and extensive tissue necrosis. It primarily affects immunocompromised individuals, particularly those with uncontrolled diabetes or hematologic malignancies.
The disease is relatively rare, with an estimated incidence of 1.7 cases per million people annually in the United States, but it carries a very high mortality rate. It occurs worldwide and is increasingly recognized in patients receiving antifungal prophylaxis that does not cover Mucorales (e.g., voriconazole).
Major risk factors include uncontrolled diabetes mellitus (especially with ketoacidosis), hematologic malignancies, organ transplantation, prolonged neutropenia, chronic steroid use, deferoxamine therapy, burns, trauma, and intravenous drug use. HIV infection and malnutrition also predispose to disease. Nosocomial outbreaks have been reported, particularly due to contaminated dressings.
Infection occurs through inhalation, ingestion, or direct inoculation of fungal spores. Once inside the host, Mucorales organisms invade blood vessels, leading to thrombosis, infarction, and necrosis, with rapid spread to adjacent tissues and possible hematogenous dissemination.
The most common causative organisms are molds from the order Mucorales, including Rhizopus, Mucor, Rhizomucor, Absidia, Cunninghamella, and Saksenaea. These fungi are ubiquitous in the environment, especially in soil and decaying organic matter.
Clinical presentation varies depending on the site of infection but is typically rapidly progressive and severe.
Rhinocerebral (craniofacial) mucormycosis, most common in diabetics, begins in the sinuses and spreads to the orbit and brain. Patients may present with facial pain, nasal congestion, black necrotic lesions on the palate or nasal mucosa, orbital swelling, vision loss, and altered mental status.
Pulmonary mucormycosis occurs mainly in neutropenic patients and presents with fever, progressive lung infiltrates, and poor response to antibiotics.
Gastrointestinal mucormycosis is more common in malnourished children and presents with abdominal pain, bleeding, or perforation.
Cutaneous mucormycosis occurs after trauma or burns and presents with necrotic ulcers, eschars, and tissue destruction.
Disseminated disease may involve the brain, liver, spleen, or heart and carries a very poor prognosis.
Diagnosis relies on early clinical suspicion and histopathological confirmation. Microscopy shows broad, nonseptate, irregularly branching hyphae. Culture may be performed from tissue samples, and imaging (CT or MRI) helps assess the extent of disease. Unlike other fungal infections, β-D-glucan tests are not useful.
Treatment requires urgent, aggressive management.
First-line therapy includes intravenous amphotericin B (liposomal formulation preferred due to lower toxicity).
Second-line or salvage therapy includes posaconazole, sometimes used in combination regimens.
Equally important are reversal of underlying risk factors (e.g., control of diabetes, reduction of immunosuppression) and prompt surgical debridement of necrotic tissue, which is often lifesaving.
Additional supportive therapies may include granulocyte transfusions, growth factors, hyperbaric oxygen therapy, and iron chelation strategies in selected cases.
The prognosis remains poor, especially if diagnosis is delayed. Untreated rhinocerebral disease is almost universally fatal within days, while even with treatment, survival in diabetic patients is approximately 50%. Outcomes are worse in immunocompromised individuals and in disseminated disease.
Complications include vascular thrombosis, brain abscesses, pulmonary dissemination, bowel infarction, hemorrhage, and widespread tissue destruction, often leading to death if not rapidly treated.
Mucormycosis is a life-threatening opportunistic fungal infection characterized by vascular invasion, thrombosis, and extensive tissue necrosis. It primarily affects immunocompromised individuals, particularly those with uncontrolled diabetes or hematologic malignancies.
The disease is relatively rare, with an estimated incidence of 1.7 cases per million people annually in the United States, but it carries a very high mortality rate. It occurs worldwide and is increasingly recognized in patients receiving antifungal prophylaxis that does not cover Mucorales (e.g., voriconazole).
Major risk factors include uncontrolled diabetes mellitus (especially with ketoacidosis), hematologic malignancies, organ transplantation, prolonged neutropenia, chronic steroid use, deferoxamine therapy, burns, trauma, and intravenous drug use. HIV infection and malnutrition also predispose to disease. Nosocomial outbreaks have been reported, particularly due to contaminated dressings.
Infection occurs through inhalation, ingestion, or direct inoculation of fungal spores. Once inside the host, Mucorales organisms invade blood vessels, leading to thrombosis, infarction, and necrosis, with rapid spread to adjacent tissues and possible hematogenous dissemination.
The most common causative organisms are molds from the order Mucorales, including Rhizopus, Mucor, Rhizomucor, Absidia, Cunninghamella, and Saksenaea. These fungi are ubiquitous in the environment, especially in soil and decaying organic matter.
Clinical presentation varies depending on the site of infection but is typically rapidly progressive and severe.
Rhinocerebral (craniofacial) mucormycosis, most common in diabetics, begins in the sinuses and spreads to the orbit and brain. Patients may present with facial pain, nasal congestion, black necrotic lesions on the palate or nasal mucosa, orbital swelling, vision loss, and altered mental status.
Pulmonary mucormycosis occurs mainly in neutropenic patients and presents with fever, progressive lung infiltrates, and poor response to antibiotics.
Gastrointestinal mucormycosis is more common in malnourished children and presents with abdominal pain, bleeding, or perforation.
Cutaneous mucormycosis occurs after trauma or burns and presents with necrotic ulcers, eschars, and tissue destruction.
Disseminated disease may involve the brain, liver, spleen, or heart and carries a very poor prognosis.
Diagnosis relies on early clinical suspicion and histopathological confirmation. Microscopy shows broad, nonseptate, irregularly branching hyphae. Culture may be performed from tissue samples, and imaging (CT or MRI) helps assess the extent of disease. Unlike other fungal infections, β-D-glucan tests are not useful.
Treatment requires urgent, aggressive management.
First-line therapy includes intravenous amphotericin B (liposomal formulation preferred due to lower toxicity).
Second-line or salvage therapy includes posaconazole, sometimes used in combination regimens.
Equally important are reversal of underlying risk factors (e.g., control of diabetes, reduction of immunosuppression) and prompt surgical debridement of necrotic tissue, which is often lifesaving.
Additional supportive therapies may include granulocyte transfusions, growth factors, hyperbaric oxygen therapy, and iron chelation strategies in selected cases.
The prognosis remains poor, especially if diagnosis is delayed. Untreated rhinocerebral disease is almost universally fatal within days, while even with treatment, survival in diabetic patients is approximately 50%. Outcomes are worse in immunocompromised individuals and in disseminated disease.
Complications include vascular thrombosis, brain abscesses, pulmonary dissemination, bowel infarction, hemorrhage, and widespread tissue destruction, often leading to death if not rapidly treated.
0 Comments
